NCT03480230 - Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Non-Small Cell Lung Cancer Stage

Interventions

DRUG

Compound 121564

Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.

Trial Locations (5)

NOT_YET_RECRUITING

King Hussein Cancer Center, Amman

RECRUITING

American University of Beirut Medical Center, Beirut

NOT_YET_RECRUITING

Bellevue Medical Center, Beirut

RECRUITING

Lebanese American University Medical Center-Rizk Hospital, Beirut

NOT_YET_RECRUITING

Hammoud Hospital University Medical Center, Sidon